Stock FLUI FLUICELL AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Fluicell AB

Equities

FLUI

SE0010831321

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:14:03 2024-05-17 EDT 		5-day change 1st Jan Change
0.0894 SEK +1.82% Intraday chart for Fluicell AB -6.49% -85.85%
05-10 Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-08 Fluicell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 51.64 65.27 233.8 267.8 38.12 17.2
Enterprise Value (EV) 1 29.41 61.83 215 247.1 13.66 14.44
P/E ratio -3.26 x -3.5 x -13.3 x -11.4 x -1.89 x -0.62 x
Yield - - - - - -
Capitalization / Revenue 42.1 x 26.2 x 50.4 x 103 x 11.7 x 5.15 x
EV / Revenue 24 x 24.9 x 46.4 x 95 x 4.2 x 4.33 x
EV / EBITDA -2.03 x -3.4 x -13.1 x -11.7 x -0.65 x -0.55 x
EV / FCF -3.44 x -5.66 x -19 x -21.9 x -0.96 x -0.92 x
FCF Yield -29.1% -17.7% -5.26% -4.57% -104% -109%
Price to Book 2.21 x 6.38 x 12.5 x 14 x 2.72 x 40.5 x
Nbr of stocks (in thousands) 7,485 7,485 11,460 13,325 14,661 27,218
Reference price 2 6.899 8.720 20.40 20.10 2.600 0.6320
Announcement Date 19-03-29 20-04-24 21-04-08 22-04-26 23-04-21 24-04-19
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1.226 2.488 4.635 2.602 3.251 3.338
EBITDA 1 -14.45 -18.16 -16.42 -21.11 -21.01 -26.27
EBIT 1 -14.78 -18.68 -17.03 -21.7 -21.73 -26.88
Operating Margin -1,205.38% -750.92% -367.34% -833.78% -668.32% -805.24%
Earnings before Tax (EBT) 1 -14.7 -18.64 -17.59 -21.69 -21.61 -26.55
Net income 1 -14.7 -18.64 -17.59 -21.69 -21.61 -26.55
Net margin -1,199.02% -749% -379.5% -833.7% -664.63% -795.51%
EPS 2 -2.118 -2.490 -1.535 -1.760 -1.373 -1.018
Free Cash Flow 1 -8.558 -10.92 -11.3 -11.3 -14.18 -15.7
FCF margin -698% -439.02% -243.86% -434.1% -436.2% -470.29%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-03-29 20-04-24 21-04-08 22-04-26 23-04-21 24-04-19
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 22.2 3.44 18.8 20.7 24.5 2.76
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -8.56 -10.9 -11.3 -11.3 -14.2 -15.7
ROE (net income / shareholders' equity) -89.2% -111% -118% -112% -102% -222%
ROA (Net income/ Total Assets) -49.2% -50.9% -47.5% -52.3% -46.2% -81.7%
Assets 1 29.85 36.63 37 41.45 46.74 32.49
Book Value Per Share 2 3.120 1.370 1.630 1.430 0.9600 0.0200
Cash Flow per Share 2 2.970 1.130 1.570 1.550 1.000 0.1000
Capex 1 1.56 0.81 0.33 0.77 1.14 -
Capex / Sales 127% 32.64% 7.14% 29.67% 34.94% -
Announcement Date 19-03-29 20-04-24 21-04-08 22-04-26 23-04-21 24-04-19
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
FLUICELL AB Stock Fluicell AB
-85.85% 2.74M
MODERNA, INC. Stock Moderna, Inc.
+33.63% 50.93B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.17B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. FLUI Stock
  4. Financials Fluicell AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW